<document page-count="7">
<page number="1">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="1" data-table="1"><tr><td>Archives of the Balkan Medical Union</td><td></td><td>vol. 54, no. 2, pp. 274-280</td></tr><tr><td>Copyright © 2019 Balkan Medical Union</td><td></td><td>June 2019</td></tr><tr><td></td><td></td><td>ORIGINAL PAPER</td></tr><tr><td colspan="3">DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE</td></tr><tr><td colspan="3">REORGANIZATION AND GLUCOSE LEVEL AS MARKERS</td></tr><tr><td colspan="3">FOR TUBERCULOSIS TREATMENT EFFECTIVENESS</td></tr><tr><td colspan="3">Olga S. SHEVCHENKO1 , Lilia D. TODORIKO2 , Iryna A. OVCHARENKO1 ,</td></tr><tr><td colspan="3">Yevheniia B. RADZISHEVSKA 1 , Olga M. SHVETS1 , Sergiy S. OVCHARENKO1 ,</td></tr><tr><td>Igor O. SEMIANIV2 , Volodymyr V. VIVSYANNUK 2</td><td></td><td></td></tr><tr><td style="text-align: right">1</td><td>Kharkiv National Medical University, Kharkiv, Ukraine</td><td></td></tr><tr><td style="text-align: right">2</td><td colspan="2">Higher State Educational Establishment „Bukovinian State Medical University“, Chernivtsi, Ukraine</td></tr><tr><td></td><td></td><td>Received 02 Apr 2019, Accepted 18 May 2019</td></tr><tr><td></td><td></td><td>https://doi.org/10.31688/ABMU.2019.54.2.08</td></tr><tr><td>A BSTRACT</td><td></td><td>R ÉSUMÉ</td></tr><tr><td>The objective of the study was to evaluate the dy-</td><td colspan="2">La dynamique du niveau de l’aldostérone, de la réor-</td></tr><tr><td>namics of reorganization of connective tissue, aldoster-</td><td colspan="2">ganisation du tissu conjonctif et du taux de glucose</td></tr><tr><td>one and glucose level as markers of favorable course of</td><td colspan="2">comme marqueurs de l’efficacité du traitement de la</td></tr><tr><td>multidrug-resistant pulmonary tuberculosis.</td><td colspan="2">tuberculose</td></tr><tr><td>Materials and methods. The study was performed</td><td></td><td></td></tr><tr><td>on 84 patients with firstly diagnosed multidrug-resist-</td><td colspan="2">Objectif. L’étude visait à évaluer la dynamique de la</td></tr><tr><td>ant pulmonary tuberculosis. Aldosterone, free and</td><td colspan="2">réorganisation du tissu conjonctif, les taux d’aldosté-</td></tr><tr><td>protein-bound hydroxyproline and glucose levels were</td><td colspan="2">rone et de glucose en tant que marqueurs de l’évolution</td></tr><tr><td>measured in all patients.</td><td colspan="2">favorable de la tuberculose pulmonaire multirésistante.</td></tr><tr><td>Results. It was found that in group I patients, free</td><td colspan="2">Matériels et méthodes. L’étude a été réalisée sur</td></tr><tr><td>hydroxyproline levels are lower than in group II during</td><td colspan="2">84 patients atteints de tuberculose pulmonaire mul-</td></tr><tr><td>the first two months of treatment for 60% at treat-</td><td colspan="2">tirésistante diagnostiquée pour la première fois. Les</td></tr><tr><td>ment onset and for 29.4% after 2 months of treatment.</td><td colspan="2">taux d’aldostérone, d’hydroxyproline et de glucose</td></tr><tr><td>There was an increase in this index during the first 2</td><td colspan="2">libres et liés aux protéines ont été mesurés chez tous</td></tr><tr><td>months of treatment in both groups. Protein-bound</td><td colspan="2">les patients.</td></tr><tr><td>Address for correspondence:</td><td colspan="2">Lilia D. TODORIKO</td></tr><tr><td colspan="3">Higher State Educational Establishment „Bukovinian State Medical</td></tr><tr><td colspan="3">University“, Chernivtsi, Ukraine</td></tr><tr><td colspan="3">Address: 2, Theatralna sq., Chernivtsi – 58002, Ukraine</td></tr><tr><td colspan="3">Email: pulmonology@bsmu.edu.ua; Phone /fax (+38 0372) 55-37-54</td></tr><tr><td colspan="3">Iryna A. OVCHARENKO</td></tr><tr><td colspan="3">Kharkiv National Medical University, Kharkiv, Ukraine</td></tr><tr><td colspan="3">Address: 61022, Prosp. Nauky, 4, Kharkiv National Medical University,</td></tr><tr><td colspan="3">Department of</td></tr><tr><td colspan="3">Phthisiology and Pulmonology, Kharkiv, Ukraine</td></tr><tr><td colspan="3">Email: arlabhf@i.ua; Phone +380673247149</td></tr></table></page>
<page number="2">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="2" data-table="1"><tr><td></td><td>Archives of the Balkan Medical Union</td></tr><tr><td>hydroxyproline level was higher in group I by 21.7%.</td><td>Résultats. Il a été constaté que, chez les patients du</td></tr><tr><td>The level of aldosterone at the treatment onset was</td><td>groupe I, les taux d’hydroxyproline libre étaient infé-</td></tr><tr><td>almost identical in both groups. After 2 months of</td><td>rieurs à ceux du groupe II pendant les deux premiers</td></tr><tr><td>treatment, its level decreased in both groups. However,</td><td>mois de traitement pour 60% au début du traitement</td></tr><tr><td>after 2 months of treatment in group I, its index was</td><td>et pour 29,4% après 2 mois de traitement. Il y avait</td></tr><tr><td>lower than in group II by 12.7%.</td><td>une augmentation de cet indice au cours des 2 pre-</td></tr><tr><td>Conclusions. Our results suggest that patients with</td><td>miers mois de traitement dans les deux groupes. Le</td></tr><tr><td>a favorable course of multidrug-resistant tuberculosis</td><td>taux d’hydroxyproline liée aux protéines était plus</td></tr><tr><td>have more pronounced decrease in aldosterone level,</td><td>élevé dans le groupe I de 21,7%. Le niveau d’aldos-</td></tr><tr><td>which may act as a pro-inflammatory agent and free</td><td>térone au traitement était presque identique dans les</td></tr><tr><td>hydroxyproline, which is a marker for the destruction</td><td>deux groupes. Après 2 mois de traitement, son niveau</td></tr><tr><td>of connective tissue. Inverse correlation between pro-</td><td>a diminué dans les deux groupes. Cependant, après 2</td></tr><tr><td>tein-bound hydroxyproline and glucose levels confirm</td><td>mois de traitement dans le groupe I, son indice était</td></tr><tr><td>the importance of normal glucose concentration for</td><td>inférieur de 12,7% à celui du groupe II.</td></tr><tr><td>repair process.</td><td>Conclusion. Nos résultats suggèrent que les patients</td></tr><tr><td></td><td>présentant une évolution favorable de la tuberculose</td></tr><tr><td>Keywords: multidrug-resistant tuberculosis, glucose</td><td>multirésistante présentent une diminution plus pro-</td></tr><tr><td>level, aldosterone, protein-bound hydroxyproline, free</td><td>noncée des taux d’aldostérone, ce qui peut agir en tant</td></tr><tr><td>hydroxyproline.</td><td>qu’agent pro-inflammatoire et en hydroxyproline libre,</td></tr><tr><td></td><td>marqueur de la destruction du tissu conjonctif. La cor-</td></tr><tr><td>Abbreviations list</td><td>rélation inversée entre les niveaux d’hydroxyproline et</td></tr><tr><td>FHP – free hydroxyproline</td><td>de glucose liés aux protéines confirme l’importance</td></tr><tr><td>HIV – Human Immunodeficiency Virus</td><td>d’une concentration en glucose normale pour le pro-</td></tr><tr><td>HP – hydroxyproline</td><td>cessus de réparation.</td></tr><tr><td>IP – intensive phase</td><td>Mots-clés: tuberculose multirésistante, taux de glu-</td></tr><tr><td>MTB – Mycobacterium tuberculosis</td><td>cose, aldostérone, hydroxyproline liée aux protéines,</td></tr><tr><td>MDR TB – Multidrug-resistant tuberculosis</td><td>hydroxyproline libre.</td></tr><tr><td>PBHP – protein-bound hydroxyproline</td><td></td></tr><tr><td>TB – tuberculosis</td><td></td></tr><tr><td>THP – total hydroxyproline</td><td></td></tr><tr><td>I NTRODUCTION</td><td>many patients complete their treatment with large</td></tr><tr><td></td><td>residual changes in the lungs, which can serve as</td></tr><tr><td>Tuberculosis is an important cause of death</td><td>a source of tuberculosis recurrence. Therefore, the</td></tr><tr><td>because of infectious diseases1 . In the last decade,</td><td></td></tr><tr><td></td><td>study of the processes of destruction and subsequent</td></tr><tr><td>the increase of the number of patients with drug-re-</td><td>reorganization of the lung tissue in patients with</td></tr><tr><td>sistant tuberculosis raised particular concerns.</td><td>MDR TB is relevant.</td></tr><tr><td>Multidrug-resistant tuberculosis (MDR TB) takes a</td><td>It is known that the formation of cavities is asso-</td></tr><tr><td>special place in the structure of resistant forms of</td><td>ciated with the destruction of the extracellular matrix</td></tr><tr><td>tuberculosis, when M. tuberculosis (MTB) is resistant</td><td>and collagen fibers, which ensure the integrity of the</td></tr><tr><td>to at least two antimicrobial agents of the first line,</td><td>lung tissue 6 . One of the destruction products of col-</td></tr><tr><td>namely isoniazid and rifampin 2 . Such patients require</td><td>lagen fibers is hydroxyproline (HP) and its fractions.</td></tr><tr><td>long-term treatment with the use of second line drugs</td><td>Free hydroxyproline (FHP) is considered a marker of</td></tr><tr><td>(aminoglycosides, 4th generation fluoroquinolones</td><td>connective tissue destruction, and protein-bound hy-</td></tr><tr><td>and others). However, the effectiveness of treatment</td><td>droxyproline (PBHP) is considered a repair marker7,8 .</td></tr><tr><td>in patients with MDR TB remains low3 .</td><td>The study of the collagen degradation products levels</td></tr><tr><td>Improving the treatment effectiveness of these</td><td>is relevant, since the destruction of lung tissue with</td></tr><tr><td>patients is one of the important factors in the fight</td><td>the subsequent formation of fibrotic changes is one of</td></tr><tr><td>against this pathology, as it helps to reduce the num-</td><td>the main pathomorphological events in tuberculosis.</td></tr><tr><td>ber of individuals in the population who can be</td><td>The state of carbohydrate metabolism has a sig-</td></tr><tr><td>sources of further spread of the disease 4 .</td><td>nificant effect on the destructive changes progres-</td></tr><tr><td>The criteria for effective treatment of patients</td><td>sion, since the presence of diabetes mellitus signifi-</td></tr><tr><td>with MDR TB include the cessation of bacterial excre-</td><td>cantly complicates the course of TB and worsens the</td></tr><tr><td>tion and the healing of pulmonary cavities5. However,</td><td>healing of destructive changes. Thus, monitoring of</td></tr><tr><td></td><td>June 2019 / 275</td></tr></table></page>
<page number="3">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="3" data-table="1"><tr><td colspan="3">Dynamics of aldosterone, connective tissue reorganization and glucose level as markers for... – SHEVCHENKO et al</td></tr><tr><td colspan="2">the carbohydrate metabolism state in patients with</td><td>using standard Direct ELISA Kit,the EiAsyTM Way</td></tr><tr><td colspan="2">pulmonary MDR TB allows early prediction of the</td><td>ALDOSTERON systems on a Labline-90 analyzer, ac-</td></tr><tr><td colspan="2">delayed mechanism of connective tissue reorganiza-</td><td>cording to the instructions.</td></tr><tr><td>tion.</td><td></td><td>Statistical processing of the obtained results was</td></tr><tr><td colspan="2">Recently, close attention has been paid to the</td><td>carried out by analyzing the contingency tables using</td></tr><tr><td colspan="2">study of aldosterone, which can act as a fibrosis fac-</td><td>the StatisticaBasicAcademic 13 for Windows software</td></tr><tr><td colspan="2">tor 9. It is known that aldosterone acts as a pro-in-</td><td>package (LicenseNumber: 139-956-866). We used the</td></tr><tr><td colspan="2">flammatory agent. However, its role in the processes</td><td>median (Me) interquartile range (Lower – lower quar-</td></tr><tr><td colspan="2">of fibrosis in tuberculosis patients is not well un-</td><td>tile, Upper – upper quartile) and sample size (min –</td></tr><tr><td colspan="2">derstood10,11 . Mainly, the role of aldosterone in the</td><td>minimum, max – maximum value). The difference</td></tr><tr><td colspan="2">tuberculous process as the main mineralocorticoid</td><td>between groups was determined by non-parametric</td></tr><tr><td colspan="2">hormone was studied12-14 .</td><td>statistics using the Mann-Whitney criteria. To study</td></tr><tr><td></td><td></td><td>the independent variables, we used the non-paramet-</td></tr><tr><td colspan="2">THE AIM OF THE STUDY(prospective cohort) was to</td><td>ric Kruskal-Wallis criteria. The correlation Spearman</td></tr><tr><td colspan="2">evaluate the dynamics of reorganization of connec-</td><td>coefficient R was calculated to find functional rela-</td></tr><tr><td colspan="2">tive tissue, aldosterone and glucose level as markers</td><td>tionships between the parameters, with statistical</td></tr><tr><td colspan="2">of favorable course of multidrug-resistant pulmonary</td><td>significance at p &lt;0.05.</td></tr><tr><td colspan="2">tuberculosis.</td><td>The study was performed according to the re-</td></tr><tr><td></td><td></td><td>quirements for researches with the participation of</td></tr><tr><td>M ATERIALS</td><td>AND METHODS</td><td>patients: Statute of the Ukrainian Association for</td></tr><tr><td></td><td></td><td>Bioethics and the GCP norms (1992), requirements</td></tr><tr><td colspan="2">The study was performed on 84 patients aged</td><td>and norms of ICH GLP (2002), typical ethics provi-</td></tr><tr><td colspan="2">18-55 years, 50 men (59.5%) and 34 women (40.5%),</td><td>sions of the Ministry of Public Health of Ukraine 66</td></tr><tr><td colspan="2">new cases of pulmonary MDR TB. Patients were</td><td>dated February 13, 2006.</td></tr><tr><td colspan="2">treated in Kharkiv Regional TB Dispensary No. 1,</td><td></td></tr><tr><td colspan="2">Ukraine, from 2014 to 2016, and at the time of the</td><td>R ESULTS</td></tr><tr><td colspan="2">study they completed the main course of chemother-</td><td></td></tr><tr><td colspan="2">apy with anti-TB drugs, according to the order of the</td><td>The study of the dynamics of collagen degrada-</td></tr><tr><td colspan="2">Ministry of Health of Ukraine No. 620 of 14.09.2014.</td><td>tion product levels showed that patients with MBR</td></tr><tr><td colspan="2">Patients with comorbidities (HIV, cardiovascular dis-</td><td>TB at the beginning of treatment, 2 and 3 months</td></tr><tr><td colspan="2">ease, chronic obstructive pulmonary disease) were</td><td>after the treatment onset had the FHP, PBHP indica-</td></tr><tr><td colspan="2">excluded from the study. Informed consent was ob-</td><td>tors presented in the Table 1.</td></tr><tr><td colspan="2">tained from all the patients included in the study.</td><td>During all monitoring periods, the patients had</td></tr><tr><td colspan="2">All patients had bacterial excretion and lung tissue</td><td>higher FHP levels. By the second month of treat-</td></tr><tr><td colspan="2">destruction.</td><td>ment, the level of FHP increased by 7.2%, while the</td></tr><tr><td colspan="2">Treatment of patients with pulmonary MDR</td><td>PBHP decreased by 6.2%. After 3 months of treat-</td></tr><tr><td colspan="2">TB requires at least 8 months of the intensive phase</td><td>ment, the level of FHP decreased by 10.2% compared</td></tr><tr><td colspan="2">(IP) of chemotherapy with anti-TB drugs. During this</td><td>with its level at the beginning of treatment and by</td></tr><tr><td colspan="2">time, patients were monitored for treatment efficacy:</td><td>18.2% compared with the previous month. The level</td></tr><tr><td colspan="2">a monthly sputum test to identify MTB, and an X-ray</td><td>of PBHP increased by 8.2% after 3 months of treat-</td></tr><tr><td colspan="2">examination 4 and 8 months after the onset of an-</td><td>ment compared with its level at the start of treatment</td></tr><tr><td colspan="2">ti-TB therapy. Depending on the results of the moni-</td><td>and by 13.9% compared with the previous month.</td></tr><tr><td colspan="2">toring, the patients were divided into groups: Group</td><td>The levels of aldosterone in patients with MDR</td></tr><tr><td colspan="2">I (n = 40) included patients in whom the cavities were</td><td>TB at the beginning of treatment, after 2 and 3</td></tr><tr><td colspan="2">closed and the bacterial excretion was stopped after 8</td><td>months from the start of treatment, are presented</td></tr><tr><td colspan="2">months of treatment – favorable course of TB; Group</td><td>in Table 2.</td></tr><tr><td colspan="2">II (n = 44) included patients with destructions and/</td><td>When comparing groups with favorable and</td></tr><tr><td colspan="2">or bacterial excretion after 8 months of treatment –</td><td>unfavorable tuberculosis, it was found that the level</td></tr><tr><td colspan="2">unfavorable course of TB.</td><td>of aldosterone was almost the same at the beginning</td></tr><tr><td colspan="2">Plasma glucose levels, total hydroxyproline</td><td>of treatment. However, after 2 months of treatment,</td></tr><tr><td colspan="2">(THP), FHP, PBHP and aldosterone levels were stud-</td><td>it decreased by 33.4% in Group I and by 25.3% in</td></tr><tr><td colspan="2">ied in all patients at the beginning of treatment, and</td><td>Group II, and its level in Group I was lower by 12.7%</td></tr><tr><td colspan="2">at 2 and 3 months after the treatment onset. THP</td><td>than in Group II (p&lt;0.05) (Fig. 1).</td></tr><tr><td colspan="2">and its fractions (mg/L) were studied by Sharayev15 .</td><td>The level of FHP was lower by 60% in patients</td></tr><tr><td colspan="2">The aldosterone levels were tested by ELISA</td><td>from Group I at the beginning of treatment, and by</td></tr><tr><td colspan="2">276 / vol. 54, no. 2</td><td></td></tr></table></page>
<page number="4">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="4" data-table="1"><tr><td colspan="9">Archives of the Balkan Medical Union</td></tr><tr><td colspan="9">Table 1. Dynamics of parameters of connective tissue reorganization markers in patients with pulmonary</td></tr><tr><td></td><td colspan="3">MDR TB (p &lt;0.05)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Parameter, units, time</td><td>Group (n=84)</td><td>mean</td><td>median</td><td>min</td><td>max</td><td>lower</td><td>upper</td><td>Stn.dev</td></tr><tr><td>FHP, mg/L, treatment onset</td><td>MDR TB</td><td style="text-align: right">0.99</td><td style="text-align: right">0.97</td><td style="text-align: right">0.45</td><td style="text-align: right">1.95</td><td style="text-align: right">0.61</td><td style="text-align: right">1.30</td><td style="text-align: right">0.439</td></tr><tr><td>FHP, mg/L, 2 months</td><td>MDR TB</td><td style="text-align: right">1.12</td><td style="text-align: right">1.04</td><td style="text-align: right">0.65</td><td style="text-align: right">1.95</td><td style="text-align: right">0.67</td><td style="text-align: right">1.63</td><td style="text-align: right">0.438</td></tr><tr><td>FHP, mg/L, 3 months</td><td>MDR TB</td><td style="text-align: right">0.88</td><td style="text-align: right">0.88</td><td style="text-align: right">0.79</td><td style="text-align: right">0.97</td><td style="text-align: right">0.79</td><td style="text-align: right">0.97</td><td style="text-align: right">0.096</td></tr><tr><td>PBHP, mg/L, treatment onset</td><td>MDR TB</td><td style="text-align: right">2.41</td><td style="text-align: right">2.25</td><td style="text-align: right">0.97</td><td style="text-align: right">5.26</td><td style="text-align: right">1.37</td><td style="text-align: right">2.98</td><td style="text-align: right">1.174</td></tr><tr><td>PBHP, mg/L, 2 months</td><td>MDR TB</td><td style="text-align: right">2.08</td><td style="text-align: right">2.11</td><td style="text-align: right">0.85</td><td style="text-align: right">4.21</td><td style="text-align: right">1.45</td><td style="text-align: right">2.5</td><td style="text-align: right">0.854</td></tr><tr><td>PBHP, mg/L, 3 months</td><td>MDR TB</td><td style="text-align: right">2.45</td><td style="text-align: right">2.45</td><td style="text-align: right">1.85</td><td style="text-align: right">3.05</td><td style="text-align: right">1.85</td><td style="text-align: right">3.05</td><td style="text-align: right">0.641</td></tr><tr><td colspan="8">Table 2. Dynamics of aldosterone in patients with pulmonary MDR TB (p &lt;0.05)</td><td></td></tr><tr><td>Parameter, units, time</td><td>Group (n=84)</td><td>mean</td><td>median</td><td>min</td><td>max</td><td>lower</td><td>upper</td><td>Sdtenv..</td></tr><tr><td>Aldosterone, mg/L, treatment onset</td><td>MDR TB</td><td style="text-align: right">93.665</td><td style="text-align: right">91.11</td><td style="text-align: right">27.81</td><td style="text-align: right">262.16</td><td style="text-align: right">47.64</td><td style="text-align: right">110.8</td><td style="text-align: right">55.9</td></tr><tr><td>Aldosterone, mg/L, 2 months</td><td>MDR TB</td><td style="text-align: right">65.716</td><td style="text-align: right">61.41</td><td style="text-align: right">39.29</td><td style="text-align: right">101.46</td><td style="text-align: right">57.99</td><td style="text-align: right">68.5</td><td style="text-align: right">16.4</td></tr><tr><td>Aldosterone, mg/L, 3 months</td><td>MDR TB</td><td style="text-align: right">59.865</td><td style="text-align: right">59.87</td><td style="text-align: right">57.91</td><td style="text-align: right">61.82</td><td style="text-align: right">57.91</td><td style="text-align: right">61.8</td><td style="text-align: right">2.1</td></tr><tr><td colspan="6">*- significantly when comparing the two groups (p&lt;0,05)</td><td></td><td></td><td></td></tr><tr><td colspan="9">Figure 1. The dynamics of aldosterone (pg/mL) in patients with different outcomes of pulmonary MDR TB treatment.</td></tr><tr><td colspan="2">29.4% after 2 months of treatment. The dynamics of</td><td colspan="7">strong inverse correlation was found between glucose</td></tr><tr><td colspan="2">its growth in Group I was 59.2%, and in Group II it<br/>was 28.9% (p&lt;0.05) (Fig. 2).</td><td colspan="7">level and PBHP (r = – 0.86, p&lt;0.05). After 2 months<br/>of treatment, a strong inverse correlation was found</td></tr><tr><td colspan="2">The level of PBHP in patients from Group II</td><td colspan="7">between aldosterone and PBHP (r = –0.83, p &lt;0.05)</td></tr><tr><td colspan="2">was higher than in Group II by 21.7%, and after 2</td><td colspan="7">and the inverse correlation of average strength be-</td></tr><tr><td colspan="2">months of treatment it was 55.5% lower (p &lt;0.05). In</td><td colspan="7">tween aldosterone and FHP (r = –0.56, p &lt;0.05).</td></tr><tr><td colspan="2">two months of treatment, it decreased by 46.2% in</td><td colspan="7"></td></tr><tr><td colspan="2">Group I, and slightly increased (by 6.9%) in Group</td><td colspan="7">D ISCUSSION</td></tr><tr><td colspan="2">II (p&lt;0.05) (Fig. 3).</td><td colspan="7"></td></tr><tr><td colspan="2">We performed a correlation analysis between col-</td><td colspan="7">The amino acid oxyproline is the product of the</td></tr><tr><td colspan="2">lagen degradation products, aldosterone, and blood</td><td colspan="7">hydrolysis of collagen and gelatin. It is a heterocyclic</td></tr><tr><td colspan="2">glucose levels. At the beginning of the treatment, a</td><td colspan="7">amino acid that is part of gelatin (13%), as well as</td></tr><tr><td colspan="2"></td><td colspan="7">June 2019 / 277</td></tr></table></page>
<page number="5">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="5" data-table="1"><tr><td colspan="2">Dynamics of aldosterone, connective tissue reorganization and glucose level as markers for... – SHEVCHENKO et al</td></tr><tr><td colspan="2">*-significantly when comparing the two groups (p&lt;0,05)</td></tr><tr><td colspan="2">Figure 2. The dynamics of free hydroxyproline (mg/L)</td></tr><tr><td colspan="2">in patients with different outcomes of pulmonary MDR TB treatment</td></tr><tr><td colspan="2">*-significantly when comparing the two groups (p&lt;0,05)</td></tr><tr><td colspan="2">Figure 3. The dynamics of protein-bound hydroxyproline (mg/L)<br/>in patients with different outcomes of pulmonary MDR TB treatment.</td></tr><tr><td>collagen. Hydroxyproline is the main marker that al-</td><td>is the product of the destruction of various forms of</td></tr><tr><td>lows to describe the processes of collagen catabolism</td><td>collagen and gelatin. The normal concentration of</td></tr><tr><td>in the body. When collagen and gelatin are destroyed,</td><td>hydroxyproline (in healthy individuals) in blood se-</td></tr><tr><td>hydroxyproline is released into the bloodstream both</td><td>rum is 12.68 μmol/L, in urine it is 172.5 mol/L15 .</td></tr><tr><td>as a free oligopeptide and in polypeptide form, since</td><td>Hydroxyproline is almost exclusively found in col-</td></tr><tr><td>it cannot be reused for the synthesis of collagen and</td><td>lagen and gelatin, so its concentration in the blood</td></tr><tr><td>gelatin. Therefore, a significant part of endogenous</td><td>and urine indicates the intensity of the destruction</td></tr><tr><td>hydroxyproline, which is found in biological fluids,</td><td>of these structures16 . In disorders of the metabolism</td></tr><tr><td>278 / vol. 54, no. 2</td><td></td></tr></table></page>
<page number="6">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="6" data-table="1"><tr><td></td><td>Archives of the Balkan Medical Union</td></tr><tr><td>of connective tissue, the level of its free fraction in-</td><td>an earlier onset of reparative changes in pulmonary</td></tr><tr><td>creases and the level of the protein-bound fraction</td><td>tissue, but a decrease in this parameter indicates a</td></tr><tr><td>decreases17. It is believed that free hydroxyproline is</td><td>limitation of the healing mechanisms in pulmonary</td></tr><tr><td>a marker of connective tissue destruction, and the</td><td>tissue. The rate of PBHP in Group II was lower than</td></tr><tr><td>protein-bound hydroxyproline is a marker of repair18 .</td><td>in group I at the beginning of treatment. In dynam-</td></tr><tr><td>A constant level of FHP and the increase in</td><td>ics, the level of this parameter in Group II changed</td></tr><tr><td>PBHP by the third month of treatment may indicate</td><td>little. This may indicate weakness of the repairing</td></tr><tr><td>a continuing destruction of pulmonary tissue and a</td><td>mechanisms in patients from this group 6 .</td></tr><tr><td>slow activation of repairing processes.</td><td>The decrease in aldosterone and blood glucose</td></tr><tr><td>Aldosterone can enhance the synthesis and accu-</td><td>levels was accompanied by an increase in parameters</td></tr><tr><td>mulation of collagen type I and III. In an experiment</td><td>characterizing the healing processes in pulmonary tis-</td></tr><tr><td>on rats, it was found that aldosterone participates in</td><td>sue, mainly due to the level of PBHP. The obtained</td></tr><tr><td>the damage of alveoli capillary membrane. A number</td><td>inverse strong correlation between the levels of PBHP</td></tr><tr><td>of studies indicate that individual pulmonary cells</td><td>responsible for the repair of connective tissue and glu-</td></tr><tr><td>have receptors to aldosterone, which indicates its par-</td><td>cose is confirmed by literature data 20 . In other words,</td></tr><tr><td>ticipation in the active transport of sodium through</td><td>in patients with elevated glucose levels, inhibition of</td></tr><tr><td>the alveoli capillary membrane. Elevated levels of</td><td>repairing processes in pulmonary tissue is observed.</td></tr><tr><td>aldosterone stimulate the growth of smooth muscle</td><td></td></tr><tr><td>cells, fibroblasts and contribute to the development</td><td>C ONCLUSIONS</td></tr><tr><td>of fibrosis in the lungs. The synthesis of collagen in</td><td></td></tr><tr><td>the pulmonary tissue is controlled by the state of the</td><td>Our results suggest that patients with a favora-</td></tr><tr><td>extracellular matrix. There is evidence that aldoster-</td><td>ble course of multidrug-resistant tuberculosis have</td></tr><tr><td>one can increase the degradation of the extracellular</td><td>more pronounced decrease in aldosterone level,</td></tr><tr><td>matrix through the activation of matrix metallopro-</td><td>which may act as a pro-inflammatory agent and free</td></tr><tr><td>teinases, some of which are destroyers of the extracel-</td><td>hydroxyproline, which is a marker for the destruction</td></tr><tr><td>lular matrix19.</td><td>of connective tissue. The presence of inverse correla-</td></tr><tr><td>Also, all patients had a decrease in the level of al-</td><td>tion links between aldosterone and hydroxyproline</td></tr><tr><td>dosterone in all periods of the study. It is known that</td><td>fractions also may indicate a link between higher</td></tr><tr><td>aldosterone can act as a proinflammatory agent, and</td><td>levels of aldosterone and processes of destruction of</td></tr><tr><td>its higher levels indicate a slower decline in the in-</td><td>lung tissue. Reducing level of aldosterone leads to a</td></tr><tr><td>flammatory response11. A reduced level of aldosterone</td><td>predominance of the healing process over the pro-</td></tr><tr><td>indicates the effectiveness of anti-TB therapy and the</td><td>cesses of degradation. This is indicated by a stronger</td></tr><tr><td>decline of inflammatory processes during treatment.</td><td>inverse correlation between the level of aldosterone</td></tr><tr><td>Significant difference between the studied pa-</td><td>and protein-bound hydroxyproline which is consid-</td></tr><tr><td>rameters in the groups with favorable and unfavora-</td><td>ered a marker of connective tissue repair. The strong</td></tr><tr><td>ble course of tuberculosis was detected only in the</td><td>inverse correlation between the level of glucose and</td></tr><tr><td>first and second months of treatment.</td><td>protein-bound hydroxyproline protein-bound gives</td></tr><tr><td>A more rapid decrease in the level of aldoster-</td><td>evidence of a decrease in repair processes in patients</td></tr><tr><td>one was found in patients with a favorable course of</td><td>with elevated glucose levels. The obtained data allow</td></tr><tr><td>tuberculosis, which may indicate a more intense in-</td><td>us to recommend the study of indicators of connec-</td></tr><tr><td>hibition of inflammation in this group of patients.</td><td>tive tissue reorganization and aldosterone in dynam-</td></tr><tr><td>This allows us to consider aldosterone as a prognostic</td><td>ics, as early markers of effective treatment of multid-</td></tr><tr><td>marker of effective treatment.</td><td>rug-resistant pulmonary tuberculosis.</td></tr><tr><td>In both groups, there was an increase in the level</td><td></td></tr><tr><td>of FHP, which indicates the continuing processes of</td><td></td></tr><tr><td>the pulmonary tissue destruction during the first 2</td><td>Compliance with Ethics Requirements:</td></tr><tr><td>months of treatment. However, the level of this pa-</td><td>„The authors declare no conflict of interest regarding</td></tr><tr><td>rameter was significantly lower in Group I than in</td><td>this article“</td></tr><tr><td>Group II, which may indicate a predominance of de-</td><td>„The work was performed according to the require-</td></tr><tr><td>struction processes over repair processes in patients</td><td>ments for researches with the participation of people:</td></tr><tr><td>with ineffective treatment of MDR TB.</td><td>Statute of the Ukrainian Association for Bioethics and the</td></tr><tr><td>In the group with a favorable course of tuber-</td><td>GCP norms (1992), requirements and norms of ICH GLP</td></tr><tr><td>culosis, there was a decrease in PBHP, while in the</td><td>(2002), ethical standards in the Helsinki Declaration of</td></tr><tr><td>group with an unfavorable course there was a mild</td><td>1975, as revised in 2008, typical ethics provisions of the</td></tr><tr><td>increase of its level. Such dynamics may indicate</td><td>Ministry of Public Health of Ukraine 66 dated February</td></tr><tr><td></td><td>June 2019 / 279</td></tr></table></page>
<page number="7">
<table data-filename="08.DYNAMICS OF ALDOSTERONE, CONNECTIVE TISSUE REORGANIZATION.pdf" data-page="7" data-table="1"><tr><td colspan="3">Dynamics of aldosterone, connective tissue reorganization and glucose level as markers for... – SHEVCHENKO et al</td></tr><tr><td colspan="2">13, 2006. The work was approved by Ethical Commission</td><td>10. Upadhyay J, Sudhindra P, Abraham G, Trivedi N.</td></tr><tr><td colspan="2">of Kharkiv National Medical University, Ukraine (Protocol</td><td>Tuberculosis of the adrenal gland: a case report and re-</td></tr><tr><td></td><td></td><td>view of the literature of infections of the adrenal gland.</td></tr><tr><td colspan="2">No 2 of 02.02.2015; chairmen – MD, professor Ospanova</td><td>International Journal of Endocrinology 2014, article ID 876037.</td></tr><tr><td colspan="2">T.S. (+ 38 050 9988242)).“</td><td>11. Seredyuk V. Role of aldosterone, mutogenic growth factors,</td></tr><tr><td></td><td>„No funding for this study“</td><td>apoptosis inducers and pulmonary arterial hypertension in</td></tr><tr><td></td><td>Acknowledgements: none</td><td>the formation and progression of chronic pulmonary heart</td></tr><tr><td></td><td></td><td>disease. Pharma Innovation Journal. 2013; 5(2):36-40.</td></tr><tr><td></td><td></td><td>12. Nagai Y, Miyata K, Sun GP, et al. Aldosterone stimulates</td></tr><tr><td></td><td></td><td>collagen gene expression and synthesis via activation</td></tr><tr><td colspan="2">R EFERENCES</td><td>of ERK1/2 in rat renal fibroblasts. Hypertension. 2005;</td></tr><tr><td></td><td></td><td>46(4):1039-1045.</td></tr><tr><td style="text-align: right">1.</td><td>Feshchenko YuI, Melnyk VM, Turchenko LV. A fight with</td><td>13. Hung CS, Chou CH, Liao CW, et al. Aldosterone induces</td></tr><tr><td></td><td>tuberculosis in Ukraine: view on a problem. Ukr Pulmonol J.</td><td>tissue inhibitor of metalloprotein expression and further</td></tr><tr><td></td><td>2016;3:5-10.</td><td>contributes to collagen accumulation. Hypertension. 2016;</td></tr><tr><td style="text-align: right">2.</td><td>Popescu G, Dumitru M, Todoriko L, et al. Comparative as-</td><td>67(6):1309-1320.</td></tr><tr><td></td><td>sessment of pulmonary tuberculosis cases from Chisinau,</td><td>14. Yareshko AG, Kulish MV, Pos OA. A role of corticosteroids</td></tr><tr><td></td><td>Iasi county and Chernivtsi region. Pneumologia. 2017;1:36-41</td><td>in treatment of the first diagnosed destructive lung tubercu-</td></tr><tr><td style="text-align: right">3.</td><td>FeshchenkoYuI, Todoriko LD, Kuzhko MM, Humeniuk MI.</td><td>losis with primary drug-resistance of Mycobacterium tuber-</td></tr><tr><td></td><td>Pathomorphosis of tuberculosis – the realities of the day,</td><td>culosis. World of Medicine and Biology. 2012;1:106-109.</td></tr><tr><td></td><td>chemoresistance as a sign of its progression. Ukr Pulmonol J</td><td>15. Sharaev PN. Method for the determination of free and</td></tr><tr><td></td><td>2018; 2:6-10.</td><td>bound hydroxyproline in serum. Lab. Delo. 1981;5:283-285.</td></tr><tr><td style="text-align: right">4.</td><td>Feshchenko YuI, Melnyk VM, Turchenko LV. A concept of</td><td>16. Marks V, Cantor Th, Mesko D, Pullmann R, Nosalova G.</td></tr><tr><td></td><td>reformation of tuberculosis healthcare system and optimiza-</td><td>Differential diagnosis by Laboratory Medicine. Springer,</td></tr><tr><td></td><td>tion of anti-tuberculosis activity in Ukraine (project). Ukr</td><td style="text-align: right">2002.</td></tr><tr><td></td><td>Pulmonol J 2015;1:5-9.</td><td>17. Hernandez-Pando R, Aguilar D, Hernandez ML, Orozco</td></tr><tr><td style="text-align: right">5.</td><td>Order of the Ministry of Health of Ukraine No. 620 dated</td><td>H, Rook G. Pulmonary tuberculosis in BALB/c mice with</td></tr><tr><td></td><td>04.09.2014 “Unified clinical protocol of primary, secondary</td><td>nonfunctional IL-4 genes: changes in the inflammatory ef-</td></tr><tr><td></td><td>(specialized) and tertiary (highly specialized) medical care“</td><td>fects of TNF-alpha and in the regulation of fibrosis. Eur J</td></tr><tr><td></td><td>Tuberculosis in adults “ Kyiv; 2014.</td><td>Immunol. 2004;34:174–183.</td></tr><tr><td style="text-align: right">6.</td><td>Tarasova LG, Streltsova EN, Kantemirova BI. Immune ge-</td><td>18. Lee CG, Homer RJ, Zhu Z, Lanone S, et al. Interleukin-13 in-</td></tr><tr><td></td><td>netic pre-conditions of collagen metabolism disorders in</td><td>duces tissue fibrosis by selectively stimulating and activating</td></tr><tr><td></td><td>tuberculosis. Tuberkulez i bolezni legkikh. 2015;11:4-9</td><td>transforming growth factor beta. J Exp Med. 2001;194:809–</td></tr><tr><td style="text-align: right">7.</td><td>Kim SH, Baek MS, Yoon DS, et al. Vitamin D inhibits ex-</td><td style="text-align: right">821.</td></tr><tr><td></td><td>pression and activity of matrix metalloproteinase in human</td><td>19. Campbell SE, Janicki JS, Weber KT. Temporal differences</td></tr><tr><td></td><td>lung fibroblasts (HFL-1) Cells. Tuberculosis and Respiratory</td><td>in fibroblast proliferation and phenotype expression in</td></tr><tr><td></td><td>Diseases. 2014;77:73-80.</td><td>response to chronic administration of angiotensin II or</td></tr><tr><td style="text-align: right">8.</td><td>Guoyao W, Fuller WB, Robert CB, et al. Proline and hy-</td><td>aldosterone. Journal of Molecular and Cellular Cardiology.</td></tr><tr><td></td><td>droxyproline metabolism: implications for animal and hu-</td><td>1995;85(27):1545-1560.</td></tr><tr><td></td><td>man nutrition. Amino Acids 2011; 40(4):1053-1063.</td><td>20. Hayashi S, Takeuchi M, Hatsuda K, et al. The impact of</td></tr><tr><td style="text-align: right">9.</td><td>Shieh FK, Kotliar E, Sam F. Aldosterone and cardiovas-</td><td>nutrition and glucose intolerance on the development of tu-</td></tr><tr><td></td><td>cular remodeling: focus on myocardial failure. Journal of</td><td>berculosis in Japan. Int J Tuberc Lung Dis. 2014;18(1):84–88.</td></tr><tr><td></td><td>Renin-Angeotensin-Aldosterone System 2004; 1(5):3-13.</td><td></td></tr><tr><td colspan="2">280 / vol. 54, no. 2</td><td></td></tr></table></page>
</document>
